2,862 Shares in iShares Biotechnology ETF (NASDAQ:IBB) Bought by Grant Private Wealth Management Inc

Grant Private Wealth Management Inc bought a new stake in iShares Biotechnology ETF (NASDAQ:IBB) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 2,862 shares of the financial services provider’s stock, valued at approximately $378,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in IBB. Main Management ETF Advisors LLC boosted its stake in iShares Biotechnology ETF by 2.5% in the 3rd quarter. Main Management ETF Advisors LLC now owns 593,370 shares of the financial services provider’s stock worth $86,395,000 after purchasing an additional 14,535 shares during the period. Raymond James Financial Inc. acquired a new position in shares of iShares Biotechnology ETF during the fourth quarter worth about $55,010,000. Gray Foundation grew its holdings in shares of iShares Biotechnology ETF by 25.2% during the fourth quarter. Gray Foundation now owns 164,872 shares of the financial services provider’s stock worth $21,798,000 after buying an additional 33,179 shares in the last quarter. Aprio Wealth Management LLC acquired a new stake in iShares Biotechnology ETF in the 4th quarter valued at approximately $18,476,000. Finally, Avalon Trust Co lifted its stake in iShares Biotechnology ETF by 0.7% in the 4th quarter. Avalon Trust Co now owns 127,893 shares of the financial services provider’s stock valued at $16,909,000 after acquiring an additional 935 shares in the last quarter. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Stock Up 1.9 %

Shares of IBB stock opened at $126.79 on Thursday. The firm has a market cap of $5.99 billion, a PE ratio of 27.83 and a beta of 0.84. iShares Biotechnology ETF has a 12 month low of $123.21 and a 12 month high of $150.57. The company’s fifty day simple moving average is $135.64 and its 200-day simple moving average is $138.50.

iShares Biotechnology ETF Increases Dividend

The company also recently declared a dividend, which was paid on Friday, March 21st. Shareholders of record on Tuesday, March 18th were paid a $0.1212 dividend. The ex-dividend date of this dividend was Tuesday, March 18th. This is a boost from iShares Biotechnology ETF’s previous dividend of $0.06.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.